All In Biotech

Drug Trial Radar · NCT00088452

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Jul 2004

Primary completion

Jan 2013

Study completion Aug 31, 2016

Sponsor

Lead sponsor
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Jul 27, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 months, up to 13 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.

Conditions

  • Childhood Absence Epilepsy
  • Petit Mal Epilepsy
  • Epilepsy
  • Seizures

Interventions

  • EthosuximideDrug

    Ethosuximide is a common treatment for childhood absence epilepsy.

  • LamotrigineDrug

    Lamotrigine is a common treatment for childhood absence epilepsy.

  • Valproic acidDrug

    Valproic acid is a common treatment for childhood absence epilepsy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind TherapyTime frame: First 16-20 weeks of double blind therapy

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • The Children's Hospital of Alabama

    Birmingham, Alabama

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California at San Diego

    La Jolla, California

  • Mattel Children's Hospital at UCLA

    Los Angeles, California

  • Children's Hospital of Denver

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Nemours Children's Clinic

    Jacksonville, Florida

  • Miami Children's Hospital

    Miami, Florida

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Washington University in St. Louis

    St Louis, Missouri

  • Women and Children's Hospital of Buffalo

    Buffalo, New York

  • NYU Comprehensive Epilepsy Center, Manhattan

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Rainbow Babies & Children's Hospital

    Cleveland, Ohio

  • Children's Hospital, Inc., PCTI

    Columbus, Ohio

  • Doernbecher Children's Hospital

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • LeBonheur Children's Medical Center

    Memphis, Tennessee

  • Dallas Pediatric Neurology Associates

    Dallas, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Texas Children's Hospital

    Houston, Texas

  • University of Utah/Primary Children's Medical Center

    Salt Lake City, Utah

  • Children's Hospital of The King's Daughter (Monarch Medical Research)

    Norfolk, Virginia

  • Children's Hospital & Regional Medical Center

    Seattle, Washington

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.